ObsEva SA (OBSV)
| Previous close | 2.5900 |
| Open | 2.5500 |
| Bid | 2.5000 x 2200 |
| Ask | 2.5300 x 4000 |
| Day's range | 2.4900 - 2.6000 |
| 52-week range | 1.8550 - 5.5500 |
| Volume | 1,593,221 |
| Avg. volume | 1,812,564 |
| Market cap | 187.505M |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4610 |
| Earnings date | 04 Aug 2021 - 09 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.67 |
- Globe Newswire
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i; agent is being studied in an area of significant unmet need Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Jersey City, N.J., Geneva, Switzerland, July 27, 2021 - Organon (NYSE: OGN), a global women’s health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health, today announced that the companies have
- Zacks
Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock?
Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.
- Globe Newswire
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia– GENEVA, Switzerland and BOSTON – July 2, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha (P
